Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women

CONTEXT: In the Women's Health Initiative estrogen plus progestin trial, after mean (SD) intervention of 5.6 (1.3) years (range 3.7 to 8.6 years) and mean follow-up of 7.9 (1.4) years, breast cancer incidence was increased by combined hormone therapy. However, breast cancer mortality results ha...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA
Autori principali: Chlebowski, Rowan T., Anderson, Garnet L., Gass, Margery, Lane, Dorothy S., Aragaki, Aaron K., Kuller, Lewis H., Manson, JoAnn E., Stefanick, Marcia L., Ockene, Judith, Sarto, Gloria E., MD, Karen C. Johnson, Wactawski-Wende, Jean, Ravdin, Peter M., Schenken, Robert, Hendrix, Susan L., Rajkovic, Aleksandar, Rohan, Thomas E., Yasmeen, Shagufta, Prentice, Ross L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5142300/
https://ncbi.nlm.nih.gov/pubmed/20959578
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2010.1500
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi